32 related articles for article (PubMed ID: 9437476)
1. Management of Hospital Formularies in Ontario: Challenges within a Local Health Integration Network.
Burke N; Bowen JM; Troyan S; Jegathisawaran J; Gosse C; Tonkin M; Kagoma S; Goeree R; Holbrook A
Can J Hosp Pharm; 2016; 69(3):187-93. PubMed ID: 27402997
[TBL] [Abstract][Full Text] [Related]
2. The role of pharmacoeconomics in formulary decision making in different hospitals in Riyadh, Saudi Arabia.
Alsultan MS
Saudi Pharm J; 2011 Jan; 19(1):51-6. PubMed ID: 23960742
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees.
Hughes D; Reynolds DJ
Clin Med (Lond); 2009 Oct; 9(5):490-2. PubMed ID: 19886115
[No Abstract] [Full Text] [Related]
4. The Committees of Fifteen and Nine.
Int Dent J (Phila); 1903 Jul; 24(7):554-556. PubMed ID: 37913122
[No Abstract] [Full Text] [Related]
5. The Two Committees.
Int Dent J (Phila); 1902 Nov; 23(11):859-860. PubMed ID: 37912995
[No Abstract] [Full Text] [Related]
6. Drug and Therapeutics (D & T) committees in Dutch hospitals: a nation-wide survey of structure, activities, and drug selection procedures.
Fijn R; Brouwers JR; Knaap RJ; De Jong-Van Den Berg LT
Br J Clin Pharmacol; 1999 Aug; 48(2):239-46. PubMed ID: 10417503
[TBL] [Abstract][Full Text] [Related]
7. The application of adverse drug reaction data to drug choice decisions made by pharmacy and therapeutics committees. An Australian perspective.
Weekes LM; Day RO
Drug Saf; 1998 Mar; 18(3):153-9. PubMed ID: 9530535
[TBL] [Abstract][Full Text] [Related]
8. Literature review on the structure and operation of Pharmacy and Therapeutics Committees.
Durán-García E; Santos-Ramos B; Puigventos-Latorre F; Ortega A
Int J Clin Pharm; 2011 Jun; 33(3):475-83. PubMed ID: 21416393
[TBL] [Abstract][Full Text] [Related]
9. Tools, information sources, and methods used in deciding on drug availability in HMOs.
Barner JC; Thomas J
Am J Health Syst Pharm; 1998 Jan; 55(1):50-6. PubMed ID: 9437475
[TBL] [Abstract][Full Text] [Related]
10. Determinants of HMO formulary adoption decisions.
Dranove D; Hughes EF; Shanley M
Health Serv Res; 2003 Feb; 38(1 Pt 1):169-90. PubMed ID: 12650387
[TBL] [Abstract][Full Text] [Related]
11. Activities, functions, and structure of pharmacy and therapeutics committees in large teaching hospitals.
Mannebach MA; Ascione FJ; Gaither CA; Bagozzi RP; Cohen IA; Ryan ML
Am J Health Syst Pharm; 1999 Apr; 56(7):622-8. PubMed ID: 10423208
[TBL] [Abstract][Full Text] [Related]
12. The formulary decision-making process in a health maintenance organisation setting.
Shepherd MD; Salzman RD
Pharmacoeconomics; 1994 Jan; 5(1):29-38. PubMed ID: 10146864
[TBL] [Abstract][Full Text] [Related]
13. Operation, formulary decision-making activities of a P & T Committee in a managed care setting.
Adams J; Richardson J
Hosp Formul; 1991 Apr; 26(4):291-4, 300-1. PubMed ID: 10109798
[TBL] [Abstract][Full Text] [Related]
14. Participation and influence of individuals and committees that decide on drug availability in HMOs.
Barner JC; Thomas J
Am J Health Syst Pharm; 1998 Jan; 55(1):56-61. PubMed ID: 9437476
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
